DEVELOPMENT OF PHARMACEUTICAL CARE TOOLS FOR PATIENTS DIAGNOSED WITH HEPATOCELLULAR CARCINOMA

Introduction: The hepatocellular carcinoma (HCC) is the sixth most common type of cancer in the world. According to Barcelona Clinical Liver Cancer, the systemic therapy, used in patients in advanced stage of HCC are oral chemotherapy drugs such as sorafenib, lenvatinibe and regorafenib. Unfortunately, chemotherapy is frequently related to expected adverse events (EAE), drug interactions (DI) and reduction of drug-related problems (DRP). These factors are significant on adherence and it influence negatively in patientsD quality of life. Pharmaceutical care is a tool for the improvement of treatment and this service requires instruments to implement the pharmacotherapeutic follow-up (PF), to measure and to monitor patients☐ EAE, DI and DRP. Objectives: Development of pharmaceutical care tools to monitor EAE, DI and DRP. Method: Descriptive study of PF forms development for pharmaceutical care, focused on HCC patients, under treatment with sorafenib, lenvatinib and regorafenibe in a general hospital in Rio de Janeiro. The EAE monitoring tool was created using each treatment labels☐. The adherence questionnaire was adapted from literature. The documents were elaborated using Therapeutic Outcomes Monitoring (TOM) method. Results: Six formularies were developed and adapted for digital format to make data compilation easier. The tool used for registering information collected from pharmaceutical consultation contains: sociodemographic data (gender, race and education); social assessment (habits such as smoking, alcohol and illicit drugs consumption); medicine (drug name, when treatment began and possible allergies to drugs or food); signs and symptoms related to the HCC diagnosis; comorbidities; information about the treatment and room for notes. The EAE monitoring forms were created for each treatment. The form contains information in the label classified as very common and common. The adherence questionnaire aims to evaluate: patients therapy adherence, his understanding of disease’s stage, his sense of trust in the healthcare professionals, patients expectations and attitude towards the treatment. The TOM method requires the development of PF tools, because it is focused for pharmaceutical care of specific illnesses. Conclusion: We hope that systematic data collection will support the stages of pharmacotherapeutic analysis, identification of DRP and action plans regarding patient care during cancer treatment and promoting patient’s safety.